What a week. The 21st Century Cures Act is now waiting President Obama’s promised signature after easy passage through Congress. President-elect Donald Trump re-stirred the drug-pricing pot with comments in Time Magazine and a reported FDA commissioner candidate who doesn’t seem... Read more »

A number of companies are pursuing ways to enlist the immune system for treating cancer. Now TCR² Therapeutics is joining the ranks with technology that it says could improve on how the body’s cancer-fighting cells respond to the disease.

It’s a good day for two young San Francisco digital health companies that combine technology with human workers as they try to help doctors make patient care more effective. Both Augmedix and Vida Health announced double-digit fundraising rounds.

Nantero, a nanotech company building a new type of computer memory that it says is stronger than steel and less dense than aluminum, has raised $21 million in new financing. The company has now raised $110 million since its founding... Read more »

Speaking at a conference in San Francisco Wednesday, geneticist Craig Venter revealed that he had just had surgery for prostate cancer three weeks ago. A health workup at his own high-end clinic, Health Nucleus, pinpointed the cancer.

We’re now living in an era where, thanks to the Internet, we have easier access to more raw information than at any other time in the planet’s history. Yet, despite these reams of data, the presence of facts has seemingly never... Read more »

The U.S. Senate has voted overwhelmingly to approve the 21st Century Cures Act, a wide-ranging healthcare spending and reform bill that aims to infuse medical research with new funding and also speed up the regulatory approval process for new drugs and... Read more »

Voyager Therapeutics this afternoon is providing very early evidence that an experimental gene therapy it’s been developing might have a chance to help patients with Parkinson’s disease for whom standard treatment is no longer working well.

We’re closing out a critical year for the fledgling virtual reality industry, which rolled out a batch of the first consumer VR headsets in 2016 in a wave of media attention. But first impressions can dampen the excitement when technical hitches... Read more »

The human body can’t repair the heart damage that leads to heart failure. But new biopharmaceutical company Tenaya Therapeutics aims to find a way by turning research from the nonprofit Gladstone Institutes into regenerative medicine treatments.

San Antonio — [Updated 12/7/2016, 12:32 p.m. See below.] StemBioSys, a small life sciences firm that sells stem cell products, has raised $2.7 million in equity and debt, according to a regulatory filing.

For many people looking for ways to treat illness or disease, the first thought is to pop a pill. Taking medication is a reactive approach to disease. But Eric Marcotulli, CEO of Elysium Health, says science is now revealing ways... Read more »

Juno Therapeutics is still mulling next steps for its lead product, an experimental cancer immunotherapy now stuck in limbo because five of 68 adult leukemia patients in its current study, a clinical trial called “Rocket,” have died from severe brain swelling... Read more »

Two years ago at the American Society of Hematology conference, excitement, not blood, was running in the streets of San Francisco. The cancer immunotherapy known as CAR-T was the star of the show, thanks to dazzling early data that showed... Read more »

For all of its noble goals, the business of recycling old electronics and mobile phones is fraught with challenges and not very profitable. Retrace, a Seattle startup that spun out of Xinova earlier this fall, believes providing better data to recyclers... Read more »

Software AG, a German software giant with 4,300 employees, has acquired San Diego-based Zementis, a specialist in machine learning and data science. Financial terms of the deal were not disclosed, according to a statement Friday, after the acquisition closed last week.... Read more »